acl at investor conference - new york, page-3

Tana
Much as I would like a GSK takeover, if you look at their past track record you would have to say ACL would neither be big enough or strategic enough.

Their big "buys"over the last twelve to eighteen months have either been in emerging markets (UCB)approx $900million, Steifel a specialist derm business with a deep pipeline ($3.5 billion) and Sirtis which has interesting science in high interest treatment areas of oncology and diabetes (approx $1.5 billion)

Of course non of that rules a GSK move out absolutely.

After all I forecast a win in the Ashes and Bledisloe...so its probably on the cards.


(This should not be used as investment advice. Always seek advice from an independent professional before making investment advice)